Abstract
The voltage-gated Cav1.2 calcium channels respond to membrane depolarization by increasing the membrane permeability to Ca2+, a major signal for cardiac muscle contraction, regulation of vascular tone and CREB-dependent transcriptional activation. CACNB2 is one of the four homologous genes coding for the auxiliary Cavβ subunits, which are important modulators of the Ca2+ channel activity. Five serious mental disorders - autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia, - and three major cardiovascular diseases - hypertension, heart failure and sudden cardiac death, - have recently been linked to the CACNB2 gene coding for the Cavβ2 subunits. Here I will focus on the Cavβ2-specific molecular determinant β2-CED as an emerging pharmacological target.
Keywords: Cav1.2 calcium channel, Cavβ subunits, CACNB2, heart failure, hypertension, mental disorders.
Current Molecular Pharmacology
Title:CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders
Volume: 8
Author(s): Nikolai M. Soldatov
Affiliation:
Keywords: Cav1.2 calcium channel, Cavβ subunits, CACNB2, heart failure, hypertension, mental disorders.
Abstract: The voltage-gated Cav1.2 calcium channels respond to membrane depolarization by increasing the membrane permeability to Ca2+, a major signal for cardiac muscle contraction, regulation of vascular tone and CREB-dependent transcriptional activation. CACNB2 is one of the four homologous genes coding for the auxiliary Cavβ subunits, which are important modulators of the Ca2+ channel activity. Five serious mental disorders - autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia, - and three major cardiovascular diseases - hypertension, heart failure and sudden cardiac death, - have recently been linked to the CACNB2 gene coding for the Cavβ2 subunits. Here I will focus on the Cavβ2-specific molecular determinant β2-CED as an emerging pharmacological target.
Export Options
About this article
Cite this article as:
Soldatov M. Nikolai, CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders, Current Molecular Pharmacology 2015; 8 (1) . https://dx.doi.org/10.2174/1874467208666150507093258
DOI https://dx.doi.org/10.2174/1874467208666150507093258 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Dietary Antioxidants as Potential Pharmacological Agents for Ischemic Stroke
Current Medicinal Chemistry Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Editorial [Hot Topic: Adrenomedullin in Hypertension and Beyond (Guest Editor: Johji Kato)]
Current Hypertension Reviews Central Blood Pressure and End-organ Damage
Current Hypertension Reviews Management of Massive Obstetric Haemorrhage
Current Women`s Health Reviews Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Innate Immunity and the Heart
Current Pharmaceutical Design Long Term Regulation of Cardiac L-Type Calcium Channel by Small G Proteins
Current Medicinal Chemistry NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Controversial Effects of Non-Steroidal Anti-Inflammatory Drugs on Bone: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Family Psychoeducation in Clinical High Risk and First-Episode Psychosis
Adolescent Psychiatry PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology